Kimberly Lynn Blackwell, MD

Adjunct Professor in the Department of Medicine
Campus mail Duke Box 3893, Durham, NC 27710
Phone (919) 668-1748
Email address

Breast cancer angiogenesis
Breast cancer in younger women
Hormonal therapy
Neoadjurant therapy for breast cancer

Current Clinical Investigations

Principal Investigator, A Phase I-II Study of Neoadjuvant Evacet/Paclitaxel/Hyperthermia in Locally Advanced Breast Cancer Patients.

Investigator, Development of Screening Markers for Breast Cancer using Circulating Immune Complexes: Collaborative Study with Diagen Medical Technologies.

Principal Investigator, Use of Plasma D-Dimer as a Predictive Marker in Colorectal Carcinoma: Correlative Science Study with Genentech, Inc.

Principal Investigator, A randomized, Phase II study of gabapentin or glutamine to prevent the peripheral neuropathy/myalgia associated with weekly taxol administration in metastatic breast and lung cancer.

Investigator, A Phase 2, Randomized, Double-Masked, Multicenter Study of Two Dose Levels of ERA-923 for the treatment of Metastatic Breast Cancer in Postmenopausal Women who have failed Tamoxifen therapy. Genetics Institute.

Investigator, A Phase I Study of Combined Doxil/Hyperthermia in Stage IV Breast Cancer.

Education and Training

  • Fellow in Hematology-Oncology, Medicine, Duke University, 1997 - 2000
  • Medical Resident, Medicine, Duke University, 1994 - 1997
  • M.D., Mayo School of Health Sciences, 1994


Cardoso, F., A. Costa, L. Norton, E. Senkus, M. Aapro, F. André, C. H. Barrios, et al. “ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†..” Ann Oncol 25, no. 10 (October 2014): 1871–88.

Full Text

Cardoso, F., A. Costa, L. Norton, E. Senkus, M. Aapro, F. André, C. H. Barrios, et al. “ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)..” Breast 23, no. 5 (October 2014): 489–502.

Full Text

Tripathy, Debu, Kathleen Harnden, Kimberly Blackwell, and Mark Robson. “Next generation sequencing and tumor mutation profiling: are we ready for routine use in the oncology clinic?.” Bmc Med 12 (August 12, 2014).

Full Text

Zagar, Timothy M., Zeljko Vujaskovic, Silvia Formenti, Hope Rugo, Franco Muggia, Brigid O’Connor, Robert Myerson, et al. “Two phase I dose-escalation/pharmacokinetics studies of low temperature liposomal doxorubicin (LTLD) and mild local hyperthermia in heavily pretreated patients with local regionally recurrent breast cancer..” Int J Hyperthermia 30, no. 5 (August 2014): 285–94.

Full Text

Aapro, M., F. Andre, K. Blackwell, E. Calvo, M. Jahanzeb, K. Papazisis, C. Porta, K. Pritchard, and A. Ravaud. “Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer..” Ann Oncol 25, no. 4 (April 2014): 763–73.

Full Text

Malin, Dmitry, Elena Strekalova, Vladimir Petrovic, Allison M. Deal, Abraham Al Ahmad, Barbara Adamo, C Ryan Miller, et al. “αB-crystallin: a novel regulator of breast cancer metastasis to the brain..” Clin Cancer Res 20, no. 1 (January 1, 2014): 56–67.

Full Text

Hamilton, Erika, Gretchen Kimmick, Judith Hopkins, P Kelly Marcom, Gloria Rocha, Renee Welch, Gloria Broadwater, and Kimberly Blackwell. “Nab-paclitaxel/bevacizumab/carboplatin chemotherapy in first-line triple negative metastatic breast cancer..” Clin Breast Cancer 13, no. 6 (December 2013): 416–20.

Full Text

Gucalp, Ayca, Sara Tolaney, Steven J. Isakoff, James N. Ingle, Minetta C. Liu, Lisa A. Carey, Kimberly Blackwell, et al. “Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer..” Clin Cancer Res 19, no. 19 (October 1, 2013): 5505–12.

Full Text

Jones, Lee W., Diane R. Fels, Miranda West, Jason D. Allen, Gloria Broadwater, William T. Barry, Lee G. Wilke, et al. “Modulation of circulating angiogenic factors and tumor biology by aerobic training in breast cancer patients receiving neoadjuvant chemotherapy..” Cancer Prev Res (Phila) 6, no. 9 (September 2013): 925–37.

Full Text

Hamilton, E. P., and K. L. Blackwell. “How can we optimize treatment of HER2-positive metastatic breast cancer?.” Oncology (Williston Park, N.Y.) 27, no. 3 (March 1, 2013).